MAB21L4

Across TCGA pan-cancer cohorts, MAB21L4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAB21L4 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAB21L4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAB21L4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where MAB21L4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	1.000	0.073	.024	11	view →
HNSC	DFS	Median	All	0.860	0.361	.022	7	view →
LSCC	DFS	Median	All	0.909	0.972	.043	2	view →
LUAD	DFS	Quartile	All	0.760	0.419	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAB21L4–CCRCC (OS)

Open the CCRCC breakdown →